The global pharmaceutical excipients market is projected to expand from USD 6.6 billion in 2022 to USD 11.8 billion by 2032, with a compound annual growth rate (CAGR) of 5.8% during the forecast period. This growth is driven by several factors, including the rising demand for pharmaceutical formulations that require excipients for improved stability, solubility, and bioavailability of active ingredients. Technological advancements, particularly in nanotechnology, are enhancing the functionality of excipients, further fueling market growth.
Recent developments in the market include Clariant’s launch of high-performing pharmaceutical ingredient solutions to address API delivery and bioavailability challenges, and Roquette’s introduction of new excipient grades for moisture-sensitive ingredients. However, the market faces challenges such as the complexity of regulatory approval processes and potential adverse reactions or contamination risks associated with excipients.
Regionally, North America and Europe dominate the market, accounting for a significant share due to advanced manufacturing practices and high adoption of new technologies. The Asia-Pacific region is expected to witness the fastest growth, driven by increasing investments in the pharmaceutical industry and rising demand for cost-effective excipients from emerging economies.
Key Takeaways
- The global pharmaceutical excipients market is projected to reach USD 11.8 billion by 2032.
- In 2022, the market value was USD 6.6 billion, indicating significant growth potential.
- The market is expected to grow at a compound annual growth rate (CAGR) of 5.8% from 2022 to 2032.
- In 2022, organic chemicals dominated the product type segment due to their non-toxic nature and efficiency.
- The oral formulations segment held the largest market share in 2022, attributed to its advantages in disease management.
- Fillers and diluents held the largest market share by functionality type due to their use in tablet and capsule formulation.
- Europe led the market in 2022 with a revenue share exceeding 38%.
- The Asia-Pacific (APAC) region is expected to grow at the highest pace among all regions covered in the report.
Get Sample PDF Report: https://market.us/report/pharmaceutical-excipients-market/request-sample/
Pharmaceutical Excipients Market Key Segments
By Product Type
- Inorganic Chemical
- Organic Chemicals
By Formulation Type
- Capsules Formulation
- Tablets Formulation
- Liquid Formulation
- Parenteral Formulation
- Oral Formulation
- Other Formulations
By Functionality Type
- Fillers & Diluents
- Suspending and Viscosity Agent
- Binders
- Flavoring Agents and Sweeteners
- Preservatives
- Coating Agents
- Other Functionality Types
Key Regions
- North America (The US, Canada, Mexico)
- Western Europe (Germany, France, The UK, Spain, Italy, Portugal, Ireland, Austria, Switzerland, Benelux, Nordic, Rest of Western Europe)
- Eastern Europe (Russia, Poland, The Czech Republic, Greece, Rest of Eastern Europe)
- APAC (China, Japan, South Korea, India, Australia & New Zealand, Indonesia, Malaysia, Philippines, Singapore, Thailand, Vietnam, Rest of APAC)
- Latin America (Brazil, Colombia, Chile, Argentina, Costa Rica, Rest of Latin America)
- Middle East & Africa (Algeria, Egypt, Israel, Kuwait, Nigeria, Saudi Arabia, South Africa, Turkey, United Arab Emirates, Rest of MEA)
Buy Directly: https://market.us/purchase-report/?report_id=12527
Key Players Analysis
Ashland Global Holdings is a leading player in the pharmaceutical excipients market, offering a diverse portfolio that includes parenteral excipients and film coating systems. The company focuses on high-value applications such as continuous manufacturing of hypromellose-based products (HPMC), which enhance bioavailability and drug stability. Their innovative Benecel DC hypromellose is notable for its efficiency in continuous manufacturing processes. Ashland’s commitment to sustainability and advanced research is evident through their extensive R&D efforts in life sciences, contributing significantly to the pharmaceutical excipients sector.
BASF SE is a prominent chemical company that provides a wide range of excipients for the pharmaceutical industry, including binders, fillers, and coatings. Their products are integral to enhancing drug formulation and delivery. BASF’s pharmaceutical excipients are designed to improve the stability, solubility, and bioavailability of active pharmaceutical ingredients (APIs). The company’s extensive portfolio and innovative approach make them a key player in the market, supporting the development of more effective and reliable pharmaceutical products.
DuPont offers a variety of excipients that play crucial roles in drug formulation and manufacturing. Their product range includes cellulosics, which are essential for creating consistent and effective oral solid dosage forms. DuPont focuses on providing high-quality, reliable excipients that meet stringent regulatory standards. Their advanced materials and scientific expertise help pharmaceutical companies achieve improved drug performance and patient outcomes. DuPont’s commitment to innovation ensures their excipients remain at the forefront of pharmaceutical technology.
Roquette Frères specializes in plant-based excipients, providing sustainable and natural solutions for pharmaceutical applications. Their portfolio includes binders, fillers, and disintegrants that enhance drug delivery and patient compliance. Roquette’s excipients are known for their high functionality and biocompatibility, making them ideal for various pharmaceutical formulations. The company’s focus on sustainability and natural ingredients aligns with the growing demand for eco-friendly pharmaceutical solutions, positioning them as a leader in the excipients market.
Evonik Industries AG is a global leader in specialty chemicals, offering a comprehensive range of excipients for the pharmaceutical industry. Their products include functional polymers that improve drug solubility, stability, and release profiles. Evonik’s expertise in polymer chemistry and drug delivery systems enables them to provide innovative solutions that enhance the efficacy and safety of pharmaceutical products. Their commitment to research and development ensures continuous advancement in excipient technology, supporting the evolving needs of the pharmaceutical sector.
Pharmaceutical Excipients Market Key Players:
- Ashland Global Holdings
- BASF SE
- DuPont
- Roquette Feres
- Evonik Industries AG
- Associated British Foods
- Archer Daniels Midland Company
- Lubrizol Corporation
- Kerry Group
- Croda International PLC
- Roquette Frères
- FMC Corporation
- Other Key Players
Pharmaceutical Excipients Market Report Scope >> Market Value (2022): USD 6.8 Billion || Forecast Revenue (2032): USD 11.8 Billion || CAGR (2023-2032): 5.8% || Base Year Estimation: 2023 || Historic Period: 2019-2022 || Forecast Period: 2024-2033.
Inquire More about report: https://market.us/report/pharmaceutical-excipients-market/#inquiry
About Market.US
Market.US is renowned for its comprehensive market research and analysis, providing customized and syndicated reports to a global clientele. Specializing in a variety of sectors, they offer strategic insights and detailed market forecasts, assisting businesses in making informed decisions. With a focus on innovation and accuracy, Market.US supports clients in over 126 countries, and maintains a strong repeat customer rate, underscoring their commitment to quality and client satisfaction. Their team excels in delivering exceptional research services, ensuring that no detail is overlooked in any target market.
Contact Details
Market.us (Powered By Prudour Pvt. Ltd.)
Contact No: +1 718 618 4351.
Email: [email protected]
Blog: https://medicalmarketreport.com/
View More Trending Reports
Medical Writing Market Will Grow Nearly USD 9.4 Billion At A Rate Of 10.4% By 2032
Dental Biomaterial Market Valuation Expected To Hit USD 3.14 Billion By 2032
Ashwagandha Market Will Reach USD 1,187 Million By 2033 And Hit Around 10.9% CAGR
Cell Culture Market Outlook: Expected To Expand To USD 18.6 Billion Upholding A 12.4% CAGR